Tofacitinib in Adult Patients With Moderate to Severe Ulcerative Colitis
NCT ID: NCT04424303
Last Updated: 2026-01-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
152 participants
OBSERVATIONAL
2020-12-04
2025-12-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission
NCT03281304
Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis
NCT04624230
This Study is to Describe and Evaluate Patients in Finland Treated With Tofacitinib for the Treatment of Ulcerative Colitis Using Real World Data.
NCT05082428
An Active Surveillance, Post-Authorization Study to Characterize the Safety of Tofacitinib in Patients With Moderately to Severely Active Ulcerative Colitis in the Real-World Setting Using Data From the United Registries for Clinical Assessment and Research (UR-CARE) in the European Union (EU)
NCT06469424
Tofacitinib Response in Ulcerative Colitis - a Real World Prospective Multi-center Study
NCT03772145
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients prescribed tofacitinib
Patients with a confirmed diagnosis of moderate to severe ulcerative colitis initiating tofacitinib as per the French summary of product characteristics (SmPC).
Tofacitinib
Observational study
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tofacitinib
Observational study
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with confirmed diagnosis of moderate to severe ulcerative colitis
* Patients for whom gastroenterologist decides to initiate treatment with tofacitinib as per the French SmPC
* Patients informed about the study procedures and receiving an information letter signed by the investigator
Exclusion Criteria
* Patients that fulfill any of the contrindications according to the latest version of the SmPC
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinique de l Europe
Amiens, , France
Hopital Sud
Amiens, , France
Hopital Jean Minjoz
Besançon, , France
Hopital de La Cote de Nacre
Caen, , France
Centre Hospitalier de Cahors
Cahors, , France
Infirmerie Protestante de Lyon
Caluire-et-Cuire, , France
Hopital Trousseau
Chambray-lès-Tours, , France
Hopital D'Estaing
Clermont-Ferrand, , France
Aphp - Hopital Beaujon
Clichy, , France
Ch Intercommunal de Creteil
Créteil, , France
Ch Dunkerque
Dunkirk, , France
Hopital Albert Michallon
La Tronche, , France
Ch Bicetre
Le Kremlin-Bicêtre, , France
CH Le Mans
Le Mans, , France
Ch Emile Roux
Le Puy-en-Velay, , France
Hopital Claude Huriez
Lille, , France
Ch Saint Joseph Saint Luc
Lyon, , France
Ch Montfermeil
Montfermeil, , France
Clinique Beau Soleil
Montpellier, , France
Hopital Saint Eloi
Montpellier, , France
Chu Nantes
Nantes, , France
Clinique Jules Verne
Nantes, , France
Hopital de L'Archet
Nice, , France
Hopital Caremeau
Nîmes, , France
Hopital Europeen Georges Pompidou
Paris, , France
Aphp - Hopital Saint Louis
Paris, , France
Groupe Hospitalier Saint Joseph
Paris, , France
Chu Bichat Claude Bernard
Paris, , France
Chu de Bordeaux - Hopital Haut Leveque
Pessac, , France
CHU LYON
Pierre-Bénite, , France
Ch Annecy Genevois
Pringy, , France
Chu Rennes
Rennes, , France
Hopital Nord
Saint-Priest-en-Jarez, , France
Clinique Pasteur
Toulouse, , France
Hopital Rangueil
Toulouse, , France
Ch Valence
Valence, , France
Ch Valenciennes
Valenciennes, , France
Groupe Hospitalier Mutualiste Les Portes du Sud
Vénissieux, , France
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TOFAst study
Identifier Type: OTHER
Identifier Source: secondary_id
A3921360
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.